Visakorpi T - Search Results

1

Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.

Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, Trapman J, Romijn JC, van Weerden WM, Jenster G. Marques RB, et al. Among authors: visakorpi t. Int J Cancer. 2005 Nov 1;117(2):221-9. doi: 10.1002/ijc.21201. Int J Cancer. 2005. PMID: 15900601

2

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Cancer Res. 1997 Jan 15;57(2):314-9. Cancer Res. 1997. PMID: 9000575

3

Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model.

Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T. Hyytinen ER, et al. Among authors: visakorpi t. Br J Cancer. 1997;75(2):190-5. doi: 10.1038/bjc.1997.32. Br J Cancer. 1997. PMID: 9010025 Free PMC article.

4

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

5

Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.

Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T. Palmberg C, et al. Among authors: visakorpi t. J Urol. 2000 Dec;164(6):1992-5. J Urol. 2000. PMID: 11061898

6

Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL, Visakorpi T. Linja MJ, et al. Among authors: visakorpi t. Cancer Res. 2001 May 1;61(9):3550-5. Cancer Res. 2001. PMID: 11325816

7

Human pHyde is not a classical tumor suppressor gene in prostate cancer.

Porkka KP, Nupponen NN, Tammela TL, Vessella RL, Visakorpi T. Porkka KP, et al. Among authors: visakorpi t. Int J Cancer. 2003 Sep 20;106(5):729-35. doi: 10.1002/ijc.11278. Int J Cancer. 2003. PMID: 12866033

8

Expression of androgen receptor coregulators in prostate cancer.

Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Jänne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T. Linja MJ, et al. Among authors: visakorpi t. Clin Cancer Res. 2004 Feb 1;10(3):1032-40. doi: 10.1158/1078-0432.ccr-0990-3. Clin Cancer Res. 2004. PMID: 14871982

9

PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.

Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, Dong JT, Petros JA, Nelson PS, Marshall FF, Zhau HE, Chung LW. Wang R, et al. Among authors: visakorpi t. Cancer Res. 2004 Mar 1;64(5):1589-94. doi: 10.1158/0008-5472.can-03-3331. Cancer Res. 2004. PMID: 14996714

10

Genetic aberrations in prostate cancer by microarray analysis.

Saramäki OR, Porkka KP, Vessella RL, Visakorpi T. Saramäki OR, et al. Among authors: visakorpi t. Int J Cancer. 2006 Sep 15;119(6):1322-9. doi: 10.1002/ijc.21976. Int J Cancer. 2006. PMID: 16642477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters